UBS maintains Insulet at Neutral, raises price target to $171 from $150

UBS kept its Neutral rating on Insulet but increased its price target to $171 from $150, suggesting a 9.5% upside from the last close. Recent analyst targets range from $167 to $200.

Original reporting
Published Nov 6, 2026, 12:40 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 12:46 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
UBS maintains Insulet at Neutral, raises price target to $171 from $150 — source image
Decision brief

The 30-second read

$PODDBullishLow
01

Why it matters

The upgrade may prompt short covering and new buying, modestly boosting the stock.

02

Market read

Analyst target raise is a modest catalyst for Insulet, offering a short‑term upside signal.

03

What to watch

Potential regulatory or reimbursement risks not reflected in the target.

Relevance 5/10Novelty 5/10Timing: today

Background

UBS analyst coverage on Insulet includes a new price target of $171, up 14% from the prior $150.

Company-level read

Ticker impact

$PODDBullishHigh confidence
Context

UBS raised its price target on Insulet to $171 from $150, indicating a bullish view.

Expected impact

likely upward pressure as investors price in the higher target

Evidence & confidence

Target increase reflects improved expectations and may attract buying interest.

Market effects

May lift sentiment in the medical device sector as analysts see growth potential.

Limited to US markets where Insulet trades.

Minimal global impact beyond sector peers.

Counterpoint

Target raise could be premature if upcoming earnings miss expectations.

Key entities

  • Insulet Corp

    Medical device maker specializing in insulin pumps.

  • UBS

    Investment bank providing research coverage on Insulet.

Related articles

$PODDMedAI 8/10

Insulet Corp (PODD) Q3 2026 Earnings Call Highlights: Revenue Up 19%, EPS Jumps 60%

Insulet Corp (PODD) reported Q3 2026 revenue up 19% and EPS up 60%. US new customer starts were flat, while global growth was low single-digits. The company expects 2027 growth to be modestly below mid-teens due to tougher comparisons and increased competition. Free cash flow for 2026 is expected to be $275 million. PBM negotiations for 2027 are ongoing, creating some uncertainty. The company plans to launch Omnipod 6 in 2027, with features aimed at improving clinical outcomes and lifestyle fit.